
## Fiorenzo Santoleri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6752397/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice. PLoS ONE, 2013, 8, e56813.	2.5	42
2	Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Acta Haematologica, 2016, 136, 45-51.	1.4	20
3	Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 467-473.	1.9	14
4	Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia. Journal of Oncology Pharmacy Practice, 2019, 25, 1035-1041.	0.9	14
5	Adherence and persistence analysis after three years in real-life of inhalation therapies used in the treatment of COPD. Current Medical Research and Opinion, 2020, 36, 2055-2061.	1.9	9
6	Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. Journal of Medical Economics, 2014, 17, 320-325.	2.1	8
7	Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis. Expert Opinion on Drug Safety, 2020, 19, 93-97.	2.4	7
8	Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis. Current Reviews in Clinical and Experimental Pharmacology, 2021, 16, 109-116.	0.8	6
9	Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study. Current Medical Research and Opinion, 2021, 37, 2061-2066.	1.9	6
10	Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature. British Journal of Clinical Pharmacology, 2022, 88, 1999-2018.	2.4	6
11	Drug utilisation pattern over 3 years in the realâ€world treatment of type II diabetes. International Journal of Clinical Practice, 2021, 75, e14120.	1.7	5
12	Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Pharmacy Practice, 2022, 35, 853-858.	1.0	4
13	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. European Journal of Hospital Pharmacy, 2023, 30, 328-332.	1.1	4
14	Cyclic Guanosine Monophosphate Role in Human Carcinoma Pathogenesis. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1555-1558.	1.1	3
15	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	1.9	3
16	Adherence and persistence analysis in patients treated with double antiplatelet therapy (DAPT) at two years in real life. Patient Education and Counseling, 2021, 104, 2012-2017.	2.2	3
17	Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting. Journal of Oncology Pharmacy Practice, 2022, 28, 24-30.	0.9	3
18	Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current Medical Research and Opinion, 2021, 37, 477-481.	1.9	2

#	Article	IF	CITATIONS
19	The impact of COVID-19 on chronic therapies: the Pescara (ASL) local health authority experience in Italy. Current Medical Research and Opinion, 2022, 38, 311-316.	1.9	2
20	Time factor in antiretroviral adherence: analysis of adherence to single-tablet regimens versus multiple-tablet regimens over a 5-year period. Drugs and Therapy Perspectives, 2018, 34, 263-268.	0.6	1
21	Real-life adherence in capecitabine therapy using two analysis methods and persistence after 6 months of treatment. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522094963.	0.9	1
22	RDD e PDD: strumenti per l'aderenza e la persistenza nelle analisi di farmacoutilizzazione: il caso degli analoghi della somatostatina (2007–2011). Pharmacoeconomics Italian Research Articles, 2013, 15, 75-82.	0.2	0
23	Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital. Future Oncology, 2019, 15, 45-51.	2.4	0
24	Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Real Life Experience. Blood, 2018, 132, 5653-5653.	1.4	0